Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017090036 - AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION

Publication Number WO/2017/090036
Publication Date 01.06.2017
International Application No. PCT/IL2016/051258
International Filing Date 22.11.2016
Chapter 2 Demand Filed 19.09.2017
IPC
A61K 31/7076 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61P 1/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 31/7076
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7076containing purines, e.g. adenosine, adenylic acid
A61K 9/0053
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0053Mouth and digestive tract, i.e. intraoral and peroral administration
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants
  • CAN-FITE BIOPHARMA LTD. [IL]/[IL]
Inventors
  • FISHMAN, Pnina
  • COHEN, Shira
Agents
  • MORAG-SELA, Tamar
Priority Data
24272323.11.2015IL
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION
(FR) LIGAND DU RÉCEPTEUR DE L'ADÉNOSINE A3 POUR LE TRAITEMENT DE L'ACCUMULATION DE GRAISSE ECTOPIQUE
Abstract
(EN) The present disclosure concerns A3AR ligand for reducing ectopic fat accumulation, particularly in fatty liver. Also provided by the present disclosure is the use of A3AR ligand for the preparation of a pharmaceutical composition for reducing such fat accumulation, method of treating a condition associates with fat accumulation making use of the ligand and kits comprising pharmaceutical compositions comprising the ligand, and instructions for use of same, for treating a condition associated with ectopic fat accumulation. In one embodiment, the present disclosure provides the use of an A3AR agonist, such as 2-Chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (C1-IB-MECA, CF102) for treating fatty liver, specifically, non-alcoholic fatty liver disease (NAFLD).
(FR) La présente invention concerne le ligand du récepteur de l'adénosine A3 pour réduire l'accumulation de graisse ectopique, en particulier dans la stéatose hépatique. La présente invention concerne également l'utilisation du ligand du récepteur de l'adénosine A3 pour la préparation d'une composition pharmaceutique permettant de réduire l'accumulation de graisse, une méthode de traitement d'un état associé à l'accumulation de graisse utilisant le ligand et des trousses comprenant des compositions pharmaceutiques comprenant le ligand, et des instructions concernant leur utilisation, pour traiter un état associé à l'accumulation de graisse ectopique. Dans un mode de réalisation, la présente invention porte sur l'utilisation d'un agoniste du récepteur de l'adénosine A3, tel que le 2-chloro-N6-(3-iodobenzyl) -adénosine-5 '-N-méthyluronamide (C1-IB-MECA, CF102) pour le traitement de la stéatose hépatique, en particulier, la stéatose hépatique non alcoolique (NAFLD).
Related patent documents
RSP-2021/0079This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau